Evidence map›Paper›PMID 32984015›Full record

ArticleFrontiers in oncology2020

Perspective: Cancer Patient Management Challenges During the COVID-19 Pandemic.

Daniela Terracciano, Carlo Buonerba, Luca Scafuri, Piergiuseppe De Berardinis, George A Calin, Alessandra Ferrajoli, Muller Fabbri, Amelia Cimmino

Abstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daniela TerraccianoDepartment of Translational Medical Sciences, University Federico II, Naples, Italy.
Carlo BuonerbaCRTR Rare Tumors Reference Center, AOU Federico II, Naples, Italy.
Luca ScafuriCRTR Rare Tumors Reference Center, AOU Federico II, Naples, Italy.
Piergiuseppe De BerardinisInstitute of Biochemistry and Cell Biology, National Research Council, Naples, Italy.
George A CalinDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Alessandra FerrajoliDivision of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Muller FabbriUniversity of Hawaii Cancer Center, Cancer Biology Program, Honolulu, HI, United States.
Amelia CimminoInstitute of Genetics and Biophysics, National Research Council, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

On March 11, 2020, the WHO has declared the coronavirus disease 2019 (COVID-19) a global pandemic. As the last few months have profoundly changed the delivery of health care in the world, we should recognize the effort of numerous comprehensive cancer centers to share experiences and knowledge to develop best practices to care for oncological patients during the COVID-19 pandemic. Patients as well as physicians must be aware of all these constraints and profound social, personal, and medical challenges posed by the tackling of this deadly disease in everyday life in order to adjust to such a completely novel scenario. This review will discuss facing the challenges and the current approaches that cancer centers in Italy and United States are adopting in order to cope with clinical and research activities.

Indexed as

cancerchemotherapycoronavirus disease 2019 (COVID-19)pandemicsevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Identifiers

PMID32984015
PMCPMC7489342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.